Work

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials

Year: 2018

Type: article

Source: European Urology Oncology

DOI: 10.1016/j.euo.2018.11.006

Authors: Guru P. Sonpavde, Gregory R. Pond, Karim Fizazi, Johann S. de Bono, Ethan M. Basch, Howard I. Scher, Matthew R. Smith

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, McMaster University, Université Paris-Sud, Institut Gustave Roussy, Institute of Cancer Research, Royal Marsden Hospital, University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Memorial Sloan-Kettering Cancer Center, Exelixis, Clovis Oncology, Eisai, Astellas Pharma, Bavarian Nordic, Genentech, EMD Serono, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2903023839

FWCI: 1.299

Cites: 10

Cited by: 22

Related to: 10